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To the Editor:
The iron chelator, deferasirox, is generally effective and well tolerated, but issues around ease of use and palatability of dispersible tablets (DTs) may limit adherence, and by extension efficacy, in some patients. The ECLIPSE trial (NCT02125877) demonstrated that deferasirox film-coated tablets (FCTs) and DT formulations had similar safety profiles during 6 months of treatment, though fewer patients treated with FCT experienced severe gastrointestinal-related adverse events and patient-reported outcomes were more favorable with FCT than with DT. 1 Absolute and relative serum ferritin changes from baseline in each treatment arm were evaluated monthly during ECLIPSE. While patients experienced similar exposure to active deferasirox with either DT or FCT, a greater reduction in serum ferritin levels from baseline to end of treatment was observed with FCT, with a geometric mean change of −431 compared with −153 ng/mL with DT.
In the absence of reported efficacy data beyond 6 months for the FCT in the clinical trial setting, this mathematical modeling analysis investigated whether the observed difference in serum ferritin levels between the 2 arms at month 6 of ECLIPSE would have translated into a sustained difference in treatment effect if the study had continued through 12 months.
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The ECLIPSE study design is described in detail elsewhere. Two candidate models, using the 12-month data from the controlled registration study ICL670A108 (NCT00061763), 3 were evaluated to describe changes from baseline in serum ferritin with deferasirox; both use log transformed serum ferritin measurement:
(1) simple exponential model (random intercept and slope model of log[serum ferritin]), where treatment effect is on lambda.
(2) Verhulst model that has a saturation effect after an initial exponential decrease, where treatment effect is on gamma.
The 1-year prospective, multicenter, and Phase II ICL670A108 study evaluated deferasirox efficacy in transfusion-dependent patients with MDS (n = 47), β-thalassemia (n = 85), Diamond-Blackfan anemia (n = 30), or other rare anemias (n = 22). Patients in this study were deferasirox-naïve, unlike most ECLIPSE patients who had received prior deferasirox. After discarding the first 3-month serum ferritin data from ICL670A108, patients were considered nondeferasirox-naive, and the subsequent serum ferritin data from months 4 to 10 were used to fit the models, and those from months 11 to 12 served to test model prediction accuracy.
The final model was selected by comparing model performance based on prediction accuracy and using out-of-sample information criteria. 5 The population and individual level predictive
properties of the final model on the out-of-sample data, including coverage, bias, and root mean square error (RMSE), were also evaluated.
In ECLIPSE, 86 patients were randomized to receive DT, and 87 patients to receive FCT. Mean (SD) patient age was 34.9 (19.3) years, and 90% had previously received iron chelation therapy. Over 24 weeks, the mean (SD) actual daily deferasirox dose was 27.5 (7. This trial data availability is in accordance with the criteria and process described on www.clinicalstudydatarequest.com.
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